期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

C-erbB-2阴性乳腺癌组织中p53、Ki-67的表达及意义 被引量：2

下载PDF
导出
摘要 选取57例C-erbB-2表达阴性的乳腺癌标本,采用免疫组化SP法检测其p53和Ki-67。结果显示,p53阳性表达率为40.35%,其表达与癌组织大小、临床分期、淋巴结转移及雌激素受体(ER)、孕激素受体(PR)表达情况有关。Ki-67阳性表达率为70.18%,其表达与癌组织大小及ER、PR表达情况有关。认为p53和Ki-67也可作为C-erbB-2表达阴性的乳腺癌患者的预后判断指标。
作者 张晓明 戚晓东 何时知 王宇
机构地区 首都医科大学附属北京同仁医院
出处 《山东医药》 CAS 北大核心 2007年第12期53-54,共2页 Shandong Medical Journal
关键词 乳腺肿瘤 乳腺癌 C—erbB-2基因 P53基因 KI-67基因
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献6

二级参考文献40

  • 1叶锋,黄冰.乳腺肿瘤中c—erbB—2癌基因产物的表达及意义[J].中华病理学杂志,1993,22(2):104-106. 被引量：25
  • 2胡勇,饶慧蓉,吴强.癌基因c─erbB─2、抗癌基因p53在乳腺癌中表达的临床病理研究[J].临床与实验病理学杂志,1995,11(1):6-10. 被引量：41
  • 3Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation [J]. Iht J Cancer, 1983,31 (1):13-20.
  • 4Hall PA, Levison DA, Woods AL, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms [J]. J Pathol, 1990, 162(4): 285-294.
  • 5Mullerat J, Deroide F, Winslet MC, et al. Proliferation and p53expression in anal cancer precursor lesions [J]. Anticancer Res,2003, 23 (3C): 2995-2999.
  • 6Liu M, Lawson G, Delos M, et al. Predictive value of the fraction of cancer cells immunolabeled for proliferating cell nuclear antigen or Ki67 in biopsies of head and neck carcinomas to identify lymph node metastasis: comparison with clinical and radiologic examinations [J]. Head Neck,2003,25(4): 280-288.
  • 7Tut VM, Braithwaite AL, Angus B, et al. Gyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53,wafl, pRb and Ki67 [J]. Br J Gancer,2001, 84(2): 270-275.
  • 8Bhatavdekar JM, Patel DD, Shah NG,et al. Prognostic significance of immunohisto-chemically localized biomarkers in stage Ⅱ and stage Ⅲ breast cancer: a multivariate analysis [J] . Ann Surg Oncol,2000, 7 (4): 305-311.
  • 9Vincent-Salomon A, Rousseau A, Jouve M, et al. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy [J]. Eur J Cancer,2004(40): 1502-1508.
  • 10Nakopoulou L, Stefanaki K, Panayotopoulou E, et al. Expression of the vascular endothelial growth factor receptor-2/Flk-1 in breast carcinomas: correlation with proliferation [J]. Hum Pathol,2002,33(9): 863-870.

共引文献137

同被引文献20

  • 1李宝江,朱志华,王军业,侯景辉,赵进明,张蓬原,姚广裕,王曦,龙浩,杨名添,戎铁.Ki67、P53、VEGF和C-erbB-2在乳腺癌组织中表达的相关性研究及其临床意义[J].癌症,2004,23(10):1176-1179. 被引量：126
  • 2Anders C,Carey L A.Understanding and treating triple-negative breast cancer[J].Oncology(Williston Park),2008,22(11):1233-1239.
  • 3Shiu K K,Tan D S,Reis-Filho J S.Development of therapeutic approaches to 'triple negative' phenotype breast cancer[J].Expert Opin Ther Targets,2008,12(9):1123-1137.
  • 4Conlin A K,Seidman A D.Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative,hormone-insensitive metastatic breast cancer:current status and future opportunities[J].Clin Breast Cancer,2008,8(3):215-223.
  • 5Silva O,Lopes G,Morgenzstern D,et al.A Phase II trial of split,low-dose docetaxel and low-dose capecitabine:a tolerable and efficacious regimen in the first-line treatment of patients with HER2/neu-negative metastatic breast cancer[J].Clin Breast Cancer,2008,8(2):162-167.
  • 6Razzak A R,Lin N U,Winer E P.Heterogeneity of breast cancer and implications of adjuvant chemotherapy[J].Breast Cancer,2008,15(1):31-34.
  • 7Bottini A,Dogliot ti L,Bersiga A,et al.p53 expression and disease outcome of breast cancer patients undergoing primary chemotherapy with ant-hracycline-containing regimens[J].Ann Oncol,2003,14(7):1156.
  • 8Askmalm M S,Carstensen J,Nordenskj?ld B,et al.Mutation and accumulation of p53 related to results of adjuvant therapy of postmenopausal breast cancer patients[J].Acta Oncol,2004,43(3):235-244.
  • 9Bull S B,Ozcelik H,Pinnaduwage D,et al.The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer[J].J Clin Oncol,2004,22(1):86-96.
  • 10Kumar S,Walia V,Ray M,et al.p53 in breast cancer:mutation and countermeasures[J].Front Bio sci,2007,12:4168-4178.

引证文献2

二级引证文献4

山东医药
2007年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部